Press Releases
-
TriGUARD 3™ Cerebral Embolic Protection Device Receives CE Mark for Use in Transcatheter Heart Procedures
TAMPA, Fla., March 10, 2020 /PRNewswire/ — Keystone Heart Ltd., a Venus Medtech Comp
March 16, 20200 Comments -
Venus Medtech Announces Agreement to Acquire Keystone Heart, LTD
Merger Establishes US and EMEA Presence for the Preeminent Chinese Structural Heart Compan
October 2, 2018 -
Keystone Heart Ltd to Accelerate Trials for Advanced Device to Protect Brain During Heart Procedures
New third-generation cerebral embolic protection device offers improvements to further gua
August 2, 2017 -
Worldwide Business with kathy ireland® Interview with Keystone Heart
Worldwide Business with kathy ireland® Highlights A Revolutionary Device Being Develope
March 28, 2017 -
Venus MedTech Partnership in China and Key Asian Markets
Keystone Heart and Venus MedTech Announce Partnership for Cerebral Embolic Protection wit
March 2, 2017 -
Keystone Heart Applauds FDA Advisory Panel
Panel feedback echoes recently published NeuroARC research guidelines CAESAREA, Israel, an
February 27, 2017 -
Delirium Significantly Associated with Brain Lesions in Patients Post-TAVR According to New Data Released at TCT 2016
According to New Data Released at TCT 2016 Delirium Significantly Associated with Brain Le
November 1, 2016 -
American Journal of Cardiology Reports Data Showing New Brain Lesions in 94% of Patients Following TAVR
Data Supports Potential Need for TriGuard™ Cerebral Embolic Protection device being deve
September 30, 2016 -
TriGuard Cerebral Protection Device Demonstrates Safety and Significant Improvements in Brain Protection in Patients Undergoing TAVR Procedures
New data presented at PCR London Valves conference TriGuard Cerebral Protection Device Dem
September 19, 2016 -
Keystone Heart Ltd. Announces First Patient Enrolled in New Study to Protect the Brain During TAVR
Supporting data to be presented at Transcatheter Valve Therapies (TVT) Conference Keystone
June 15, 2016